@entity286 use as contributory factor in XXXX .

@entity1 @entity286 @entity10189 @entity1066 @entity3303 @entity2275
OBJECTIVE: To find out the association of @entity286 as a contributory factor in @entity1 presenting with @entity10189 ( @entity10189 ). DESIGN: A descriptive case study. PLACE AND DURATION OF STUDY: Department of Medicine, Postgraduate Medical Institute, Lady Reading Hospital, Peshawar, from May 2001 to April 2002. SUBJECTS AND METHODS: A total number of 100 consecutive @entity1 , 76 males and 24 females, with endoscopically proven peptic @entity1066 were enrolled in the study. The ages of the @entity1 ranged from 25 to 70 years; with mean age of 48 years + 12.26 standard deviations, (mean age of @entity1 49 years + 12.88 SD, and mean age of @entity1 45 years + 9.67 SD). All the @entity1 underwent endoscopy after an overnight fast, using @entity3303 (4% solution or jelly) as topical anaesthetic, with Pentax FG29 video-endoscope. RESULTS: Fifty-six percent of all the @entity1 with @entity10189 used @entity286 , 33% as cigarette, 18% took it as naswar and 5% of @entity1 used it in both the forms. Of these, 85.7% (48/56) @entity1 had duodenal @entity1066 and 14.3% (8/56) @entity1 had @entity2275 . All these @entity1 were male, none of the female @entity1 used @entity286 in any form. Moreover, 40% of @entity10189 @entity1 reported long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). CONCLUSION: This study supports the view that use of @entity286 is associated with @entity10189 in @entity1 .
